Corporate News FDA approves first generic of Novo Nordisk’s Victoza by Contributor since / Followers 4 months ago Hailshadow/iStock via Getty Images The U.S. FDA has approved the first generic version of Novo Nordisk’s (NVO) GLP-1 for type 2 diabetes, Victoza (liraglutide). The approval was granted to Hikma Pharmaceuticals USA. The agency noted that brand-named Victoza is currently in shortage. An authorized Tags: TEVA Continue Reading Previous Starbucks shares fall for the eighth consecutive sessionNext Chase Berkshire Hathaway Into More Occidental Petroleum Leave a Reply Cancel replyYour email address will not be published. Required fields are marked *Comment * Name * Email * Website Save my name, email, and website in this browser for the next time I comment. Δ
